Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: video (2)

Transcript: Q2 2025 Earnings Call
investorvideo
Transcript: Q2 2025 Earnings CallAugust 13, 2025
eXoZymes details biomanufacturing breakthrough: 4 grams of NCT with over 99% purity
press releaseinvestornutraceuticalsvideoscience
eXoZymes details biomanufacturing breakthrough: 4 grams of NCT with over 99% purityJuly 29, 2025
eXoZymes biomanufacturing breakthrough: From concept to gram-scale NCT in only 5 months
press releaseinvestornutraceuticalsvideoscience
eXoZymes biomanufacturing breakthrough: From concept to gram-scale NCT in only 5 monthsJuly 22, 2025
World Bio Markets: AI and Machine Learning - The Silver Bullet we Must Not Dodge
press clippingsvideo
World Bio Markets: AI and Machine Learning - The Silver Bullet we Must Not DodgeJuly 2, 2025
Chris Marlett, MDB Capital
investorpress clippingsvideo
Slack Capital interview: Chris Marlett, Chairman of the BoardMay 22, 2025
Slack Capital interview: Damien Perriman, CCO
investorpress clippingsvideo
Slack Capital interview: Damien Perriman, CCOMay 20, 2025
Tyler Korman
investorpress clippingsvideo
Slack Capital interview: Tyler Korman, VP of ResearchMay 15, 2025
Slack Capital: EXOZ investment report and CEO interview
heltzeninvestorpress clippingsvideo
Slack Capital: EXOZ investment report and CEO interviewMay 13, 2025
AI transforming biotechnology: From form with AlphaFold to function with exozymes
investorvideoscience
AI transforming biotechnology: From form with AlphaFold to function with exozymesApril 28, 2025
Dr. Tyler Korman, co-founder and VP of Research at eXoZymes, is excited about the 'exozymes' cover story in GEN Biotechnology, which is freely available as an Open Access paper.
press releaseinvestorvideoscience
GEN Biotechnology cover story: Bringing clarity and precision to the cell-free space by introducing exozymesApril 21, 2025
Previous page
Page 2 of 4
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark